Meeting
2012 ASCO Annual Meeting
Randomized phase II trial of erlotinib (E) plus high-dose celecoxib (HD-C) or placebo (P) in advanced non-small cell lung cancer.
Authors
Karen L. Reckamp
City of Hope, Duarte, CA
Karen L. Reckamp , Marianna Koczywas , Mihaela C. Cristea , Jonathan Dowell , Brian Gardner , Ginger L Milne , Robert A. Figlin , Robert M. Elashoff , Steven M. Dubinett
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer - Non-small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT00499655
Citation
J Clin Oncol 30, 2012 (suppl; abstr 7518)
DOI
10.1200/jco.2012.30.15_suppl.7518
Abstract #
7518
Poster Bd #
8
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase II study of the AKT inhibitor MK-2206 plus erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who progressed on prior erlotinib: A California Cancer Consortium Phase II trial (NCI 8698).
First Author: Primo Lara Jr.
Poster
2012 ASCO Annual Meeting
A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens.
First Author: Li Zhang
Poster
2023 ASCO Annual Meeting
Phase II trial of lazertinib in epidermal growth factor receptor (EGFR) mutation-positive (M+), metastatic non-small cell lung cancer (NSCLC) patients with asymptomatic or mild symptomatic brain metastases after failure of EGFR tyrosine kinase inhibitor (TKI) (KCSG LU20-15).
First Author: Min Hee Hong
Poster
2021 ASCO Annual Meeting
A multicenter, randomized, double-blind study of gefitinib in combination with anlotinib or placebo in previously untreated patients with EGFR mutation-positive advanced non-small cell lung cancer (FL-ALTER).
First Author: Li Zhang